The engineered T cells conferring the AFP epitope–specific T cell receptor (TCR-T) or chimeric antigen receptor (CAR-T) is another strategy for HCC treatment (7, 8, 24–26). The gene discussed is AFP; the disease is hepatocellular carcinoma.